RxDoctor Payments Data

Victor Vasquez, PA

Medical · Bloomfield, CTNPI 1972217446

Payments from drug & device makers

$2,266in general payments, 2019–2025

Across 88 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$505
  • AstraZeneca$431
  • Amgen$362
  • Exact Sciences$187
  • Lilly USA, LLC$105
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$73
  • plus $604 from 18 others

What the payments were for

  • Food & beverage$2,265100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,266 in reported general payments places this provider in the 80th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,222
Medicare patients
132
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin72$87,154
OzempicSemaglutide13$23,762
EliquisApixaban24$20,736
JanuviaSitagliptin Phosphate14$17,399
Lagevrio (Eua)Molnupiravir16$1,059
Fluticasone Propionate64$920
Amlodipine Besylate142$712
Valsartan39$614
Pregabalin26$572
Atorvastatin Calcium84$527
Escitalopram Oxalate39$472
Losartan Potassium56$467
Levothyroxine Sodium27$352
Rosuvastatin Calcium46$324
Doxycycline Hyclate43$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$505$23,76213 claims
PfizerEliquis$44$20,73624 claims
MerckJanuvia, Lagevrio (Eua)$42$18,45830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 592 medical providers in Connecticut.

Other medical in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →